Study of Non-Invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury After Acute Ischemic Stroke Due to Large Vessel Occlusion
Led by Washington University School of Medicine · Updated on 2026-04-13
65
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effects of non-invasive transcutaneous auricular vagal nerve stimulation taVNS on inflammation and brain injury markers in patients who experience ischemic strokes caused by large vessel occlusions LVO. LVO strokes often result in severe disability or death, and current treatments have limitations. The study explores if adding taVNS to standard care can reduce inflammation and brain injury, potentially improving recovery after stroke.
Participants will be randomly assigned to one of two groups one receiving taVNS and the other receiving sham stimulation without electrical current. All patients will wear a device fitted with an electrode on the left ear. Stimulation sessions will be conducted twice daily for 20 minutes during the hospital stay, using specific electrical parameters. The sham group will have the device attached but without actual stimulation. The study includes a control comparison to monitor differences between real and sham stimulation.
During the study, researchers will collect blood samples on admission, day 0, and every 1.5 days up to day 7 or discharge to measure inflammatory markers and brain injury proteins. They will also monitor for skin irritation at the stimulation site daily. Clinical assessments such as the NIH Stroke Scale and modified Rankin Scale will be used to evaluate neurological outcomes over 7 and 90 days. The total participation length depends on hospital stay and follow-up visits within the study timeline.
CONDITIONS
Brief Title
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
Research Team
A
Angela Birke, MS
O
Osvaldo Laurido-Soto, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Active VNS Treatment
Sham Comparator
What it is
Non-invasive stimulation of the auricular branch of the vagus nerve using a transcutaneous device intended to modulate inflammation and brain injury after stroke.
Device placement without electricity applied to the auricular branch of the vagus nerve; serves as the sham comparator to control for placebo and procedural effects.
Role in Trial
Active device arm to assess whether vagal stimulation reduces inflammation and brain injury biomarkers after acute stroke.
Comparator arm to separate physiological effects of stimulation from placebo and device placement effects.
Primary use
Investigational therapy aiming to reduce inflammation and injury-related blood biomarkers after large vessel occlusion stroke.
Sham stimulation to enable blinded comparison with active vagal nerve stimulation for detection of real versus placebo effects on biomarkers.
How it is given or performed
Device delivers stimulation through the skin of the ear (auricular branch of vagus nerve) using an externally applied stimulator. Sessions occur after patient presents with stroke, within 24 hours of symptom discovery.
Device is placed but no electric stimulation is applied; procedure mimics active treatment for blinding purposes.
Evidence status
Published data from a prospective randomized trial in large vessel occlusion stroke patients support reductions in key blood inflammatory biomarkers when active stimulation is applied.
Sham stimulation does not produce the same reduction in blood inflammatory biomarkers as active stimulation in published trial data.
Important limitations
Current clinical evidence is limited to biomarker outcomes; impact on neurological recovery or long-term disability remains unproven. The device is investigational in this setting.
Sham comparator provides necessary control for placebo effects but does not represent standard clinical treatment for acute ischemic stroke.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 99Years
All Genders
Eligibility Criteria
You may qualify if you...
Adult patients who present with acute ischemic strokes due to large vessel occlusions
You will not qualify if you...
Younger than 18 years old
Patients with presumed chronic large vessel occlusions
NIH Stroke Scale (NIHSS) less than 6
Pre-morbid modified Rankin score (mRS) greater than 2
Unable to start treatment within 24 hours from symptom discovery
Chronic or acute infection, recent surgery, or active immune disease
Life expectancy less than 3 months
Undergoing active cancer or immunosuppressive/modulating therapy
Sustained bradycardia on arrival with heart rate less than 50 beats per minute
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 7 days or until discharge
Participants receive transcutaneous auricular vagus nerve stimulation or sham stimulation twice daily during the inpatient period to reduce inflammation and brain injury following acute ischemic stroke.
Twice daily stimulation sessions during inpatient stay
Follow-up
Duration - Up to 90 days
Participants are monitored for neurological recovery and functional outcomes after treatment ends.
1 visit at 90 days for functional assessment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase II Study of MT200605 for Treating Acute Ischemic Stroke
Randomized, Double-Blind, Placebo-Controlled Trial in Adults 18 to 80 Years
Comparing Cyclic Plunger and Static Manual Aspiration Thrombectomy Techniques
for Acute Large Vessel Occlusion Stroke Using Raptor Aspiration Catheter
Study to Test Safety and Effectiveness of Super-Bore 87F Aspiration Catheters
for Treating Acute Blockages in Large Brain Arteries
Evaluation of B2065 Cell Injection Safety and Preliminary Effectiveness in Adults with Acute Ischemic Stroke
Randomized, Double-Blind Trial Evaluating Safety and Effects of TAK-755 Compared to Placebo in Adults with Acute Ischemic Stroke
Open-Label Study Evaluating Multiple Doses of LT3001 to Restore Arterial Blood Flow in Adults With Acute Ischemic Stroke
Evaluating Intravenous Tenecteplase Versus Standard Care for Adults With Acute Ischemic Stroke More Than 4.5 Hours After Last Known Well
Multicenter Registry Study of Endovascular Treatment for Acute Ischemic Stroke
Clinical Study of Stroke Recurrence and Characteristics in Patients With Acute Ischemic Stroke and Active Cancer A Multicenter Prospective Observational Study
Treatment of Acute Stroke Caused by Carotid Artery Bifurcation Using Micronet-Covered CGuard Stent with Flow Reversal and Thrombus Removal